GFAP and Alzheimer disease: A multicentric study involving a clinical cohort of PET-Aβ-positive MCI, AD and positive DAT scan or MIBG DLB subjects showed that higher levels of GFAP were found in both AD and DLB patients, p-tau181 modestly discriminated MCI + AD cases from DLB, while Αβ42/40, Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) poorly classified the same cohorts [64].